Aljedai joined SPIMACO in 2023 and assumed his current role in April 2025. In H1 2026, SPIMACO generated $244.5 million in revenues and had $1.2 billion in total assets. In 2026, it launched its dedicated biotechnology arm, SPIMACO Bio, which partnered last June with Genetix Biotherapeutics to localize cell and gene therapies across the Middle East. The company also acquired an additional stake in ENAYAH. Aljedai is also founding president of the Saudi Society of Clinical Pharmacy, and professor at the College of Pharmacy & College of Medicine at Alfaisal University.